Document:

Accelerated
Clinical Trial Agreement

 

This
Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of July 23, 2018 (“Effective Date”)
by and between Thomas Jefferson University, a Pennsylvania non-profit corporation (“Institution”), having an address
at 125 S. 9th Street, Second Floor Sheridan, Philadelphia, PA 19107, and Cancer Insight, LLC, a limited liability company having
its principal place of business at 110 East Houston Street, Floor Seven, San Antonio, TX 78205 (“CRO”). CRO and Institution
are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”

 

WHEREAS,
CRO has been engaged by BriaCell Therapeutics Corp. (the “Sponsor”) to arrange and administer a multi-center clinical
trial funded by Sponsor to determine the safety and efficacy of Sponsor’s product;

 

WHEREAS,
Sponsor is a for-profit organization that intends to conduct a sponsored multi-center clinical trial, described in 1.1 below,
involving the use of certain diagnostic(s), drug(s), devices(s), or biologic(s) provided by Sponsor and desires that Institution
participate in such clinical trial;

 

WHEREAS,
Institution, Sponsor and CRO have agreed to use the ACTA, to accelerate the process of translating laboratory discoveries
into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and
translational researchers;

 

WHEREAS,
the Institution has appropriate facilities and personnel with the qualification, training, knowledge, and experience necessary
to conduct such a clinical trial; and

 

WHEREAS,
the Study contemplated by this Agreement is of interest and benefit to Institution, Sponsor and CRO, and will further the
instructional and research objectives of Institution in a manner consistent with its status as a research and health care institution;

 

NOW,
THEREFORE, in consideration for the mutual promises made in this Agreement and for valid consideration, the Parties agree
as follows:

 

1.
Scope of Agreement

 

1.1.
Institution will undertake a sponsored multi-center clinical trial (“Study”) described in the protocol entitled
“A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent Breast Cancer
Patients in Combination with Ipilimumab or Pembrolizumab,” and having a protocol designation of BRI-ROL-001, which is
incorporated herein as Exhibit A (“Protocol”). Institution will use its reasonable efforts to only recruit
subjects in accordance with the Protocol. The Study will be conducted by the Institution under the direction of Saveri Bhattacharya,
DO., an employee of Institution (“Principal Investigator”).

 

1.2.
In the event of any conflict between the terms and conditions of this Agreement and the Protocol or between this Agreement and
any of its Exhibits, the terms and conditions of the Protocol shall control with respect to matters of the clinical conduct of
the Study, and the terms of this Agreement shall control with respect to all other matters.

 

1.3.
Unless otherwise agreed to by the Parties, Sponsor and/or CRO will provide to Institution on a timely basis, without charge, the
required quantities of properly-labeled Sponsor drug(s) or biologics(s) (“Study Drug”) and/or device(s) (“Study
Device”) and other materials (e.g., Investigator’s Brochure, handling and storage instructions, and, if applicable,
placebo) necessary for Institution to conduct the Study in accordance with the Protocol. Unless stated otherwise in writing by
Sponsor, all such items are and will remain the sole property of Sponsor until administered or dispensed to Study subjects during
the course of the Study. Receipt, storage, and handling of Study Drug or Study Device will be in compliance with all applicable
laws and regulations, the Protocol, and CRO’s or Sponsor’s instructions.

 

    	1

    	 

    

 

1.4.
CRO and Institution shall comply with and conduct all aspects of the Study in compliance with all applicable federal, state, and
local laws and regulations, including generally accepted standards of good clinical practice as adopted by current FDA regulations
and statutes and regulations of the U.S. Government relating to exportation of technical data, computer software, laboratory prototypes,
and other commodities as applicable to academic institutions. Institution will only allow individuals who are appropriately trained
and qualified to assist in the conduct of the Study.

 

1.5.
Institution shall obtain IRB approval for this Study and proof thereof shall be provided to CRO. Initiation of the Protocol and
Institution’s obligation to conduct the Study shall not begin until IRB approval is obtained. Institution shall obtain from
each subject, prior to the subject’s participation in the Study, a signed informed consent and necessary authorization to
disclose health information to CRO and/or Sponsor in a form approved in writing by the IRB or a waiver of consent as directed
by the IRB and further provided that the informed consent is consistent with Institution’s policies. Sponsor agrees that
the Protocol shall be amended to the extent the IRB makes or conditions other requirements.

 

1.6.
Sponsor agrees to provide Institution with any data and safety monitoring reports related to the Study, and Institution agrees
they will be submitted to the IRB as required. During the Study and for at least two (2) years following the completion of the
Study at all sites, Sponsor shall promptly provide Institution and Principal Investigator with the written report of any findings,
including Study results and any routine monitoring findings in site monitoring reports, and data safety monitoring committee reports
including, but not limited to, data and safety analyses, and any Study information that may (i) affect the safety and welfare
of current or former Study subjects, or (ii) influence the conduct of the Study. Institution and/or Principal Investigator will
communicate findings to the IRB and Study subjects, as appropriate. Institution shall promptly inform Sponsor of any urgent safety
measures as instructed in the Protocol or breaches of the Protocol of which Institution becomes aware.

 

1.7
If the Principal Investigator determines in his/her best medical judgment that a deviation from the Protocol is necessary to eliminate
an apparent immediate hazard to the health or safety of any subject participating in the Study, he or she may deviate from the
Protocol; provided, however, that the Principal Investigator shall (and the Institution shall ensure that the Principal Investigator
shall) (i) at all times act in accordance with generally accepted standards of clinical study and medical practice and any and
all applicable federal, state or local laws and regulations, and (ii) promptly notify Sponsor in writing of the facts giving rise
to the need for the deviation and the alternate procedures followed. Except as provided for in the previous sentence, for the
avoidance of doubt, neither the Principal Investigator nor the Institution shall amend or deviate from the Protocol without the
prior written approval of Sponsor and, as appropriate, the IRB and the FDA, in accordance with FDA requirements under 21 C.F.R.
§ 312.30 and any applicable foreign regulatory agency in accordance with applicable laws and regulations.

 

1.8.
Institution acknowledges CRO’s right to assign or transfer, in whole or in part, with notice to Institution, any of its
rights or obligations under this Agreement to the Sponsor or Sponsor’s designate.

 

    	2

    	 

    

 

2.
Payments

 

Sponsor
will provide financial support for the Study and will provide such funds to CRO who will pay Institution in accordance with the
budget attached as Exhibit B (“Budget”) on a prorated basis, according to the actual work completed and any
non-cancelable obligated expenses, for subjects who are enrolled into the Study. The Parties acknowledge that the Budget amounts
represent an equitable exchange for the conduct of the Study in light of the professional time and expenses required for the performance
of the Study.

 

In
addition to other necessary routing information detailed in Exhibit B, each payment shall clearly reference the Study Protocol
Number and PI name.

 

For
administrative convenience, various Study contact information may be attached hereto and incorporated by reference as Exhibit
C, entitled, “Administrative & Study Points of Contact.”

 

The
Institution’s tax identification number is: 23-1352651

 

3.
Confidentiality

 

3.1.
It is anticipated that in the performance of this Agreement, Sponsor and/or CRO on behalf of Sponsor may need to disclose to Institution
information which is considered confidential. The rights and obligations of the Parties with respect to such information are as
follows:

 

“Confidential
Information” refers to information of any kind which is disclosed to the Institution by Sponsor and/or CRO on behalf of
Sponsor for purposes of conducting the Study or Data (as defined below in Section 4) which:

 

	 	a)	by appropriate
marking, is identified as confidential and proprietary at the time of disclosure;
	 	 	 
	 	b)	if disclosed
orally, is identified in a marked writing within thirty (30) days as being confidential.

 

Sponsor
and/or CRO on behalf of Sponsor will make reasonable efforts to mark Confidential Information as stated in (a) and (b) above.
However, to the extent such marking is not practicable, then in the absence of written markings, information disclosed (written
or verbal) that a reasonable person familiar with the Study would consider it to be confidential or proprietary from the context
or circumstances of disclosure shall be deemed as such.

 

Notwithstanding
the foregoing, Data and results generated in the course of conducting the Study are not Confidential Information for publishing
purposes in accordance with Section 9 of this Agreement. Institution agrees, for a period of five (5) years following the termination
or expiration of this Agreement, to use reasonable efforts, no less than the protection given their own confidential information,
to use Confidential Information received from Sponsor and/or CRO on behalf of Sponsor in accordance with this Section.

 

Institution
agrees to use Sponsor’s Confidential Information solely as allowed by this Agreement, and for the purposes of conducting
the Study. Institution agrees to make Sponsor’s Confidential Information available only to those of its, or its affiliated
hospitals’ employees, IRB members, personnel, agents, consultants, and vendors, and approved subcontractors, as applicable,
who require access to it in the performance of this Study, and are subject to similar terms of confidentiality.

 

    	3

    	 

    

 

3.2.
The obligation of nondisclosure does not apply with respect to any of the Confidential Information that:

 

	 	a)
    	is
    or becomes public knowledge through no breach of this Agreement by Institution;
	 	 	 
	 	b)
    	is
    disclosed to Institution by a third party entitled to disclose such information without known obligation of confidentiality;
	 	 	 
	 	c)
    	is
    already known or is independently developed by Institution without use of Sponsor’s Confidential Information as shown
    by Institution’s contemporaneous written records;
	 	 	 
	 	d)
    	is
    necessary to obtain IRB approval of Study or required to be included in the written information summary provided to Study
    subject(s) and/or informed consent form;
	 	 	 
	 	e)
    	is
    released with the prior written consent of the Sponsor; or
	 	 	 
	 	f)
    	is
    required to support the medical care of a Study Subject.

 

3.3.
Institution may disclose Confidential Information to the extent that it is required to be produced pursuant to a requirement of
applicable law, IRB, government agency, an order of a court of competent jurisdiction, or a facially valid administrative, Congressional,
or other subpoena, provided that Institution, subject to the requirement, order, or subpoena, promptly notifies Sponsor. To the
extent allowed under applicable law, Sponsor may seek to limit the scope of such disclosure and/or seek to obtain a protective
order. Institution will disclose only the minimum amount of Confidential Information necessary to comply with law or court order
as advised by Institution’s legal counsel.

 

3.4.
No license or other right is created or granted hereby, except the specific right to conduct the Study as set forth by Protocol
and under terms of this Agreement, nor shall any license or other right with respect to the subject matter hereof be created or
granted except by the prior written agreement of the Parties duly signed by their authorized representatives.

 

3.5.
Upon Sponsor’s and/or CRO’s written request, Institution agrees to return all Confidential Information supplied to
it by Sponsor and/or CRO on behalf of Sponsor at Sponsor’s expense pursuant to this Agreement except that Institution may
retain such Confidential Information in a secure location for purposes of identifying and satisfying its obligations and exercising
its rights under this Agreement.

 

3.6
Institution may disclose the existence of this Agreement and any additional information necessary to ensure compliance with applicable
Federal, State and Institutional policies, regulations, and laws. Institution reserves the right to disclose information to third
party payors or government agencies in order to obtain reimbursement for medical services provided to study enrollees that are
not otherwise reimbursed by the Sponsor.

 

Notwithstanding
the foregoing, Sponsor shall cooperate and authorize release of data, which is the subject of this Study, to Institution’s
internal committees as required by accrediting agencies or other governmental agencies. If required to report such data to any
governmental authority or agency, Institution shall use all reasonable efforts to maintain the confidentiality of such data.

 

    	4

    	 

    

 

4.
Data Use/Ownership

 

“Data”
shall mean all data and information generated by Institution as a result of conducting the Study in accordance with the IRB approved
Protocol. Data does not include original Study subject or patient medical records, research notebooks, source documents, or other
routine internal documents kept in the Institution’s ordinary course of business operations, which shall remain the sole
and exclusive property of the Institution or medical provider. Sponsor owns and has the right to use the Data in accordance with
the signed informed consent and authorization form, applicable laws, and the terms of this Agreement. Notwithstanding any licenses
or other rights granted to Sponsor herein, but in accordance with the confidentiality and publication sections herein, Institution
shall retain the right to use the Data and results for its publication, IRB, regulatory, legal, clinical, educational, and internal
research purposes.

 

5.
HIPAA/HIPAA Privacy

 

5.1.
Institution shall comply with applicable laws and regulations, as amended from time to time, including without limitation, the
Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (HIPAA) with respect to the collection,
use, storage, and disclosure of Protected Health Information (PHI) as defined in HIPAA. CRO and Sponsor, through its agreement
with CRO, shall collect, use, store, access, and disclose PHI collected from Study subjects only as permitted by the IRB approved
informed consent form or HIPAA authorization form obtained from a Study subject. Sponsor will collect, use, store, and disclose
any Subject Material, defined in Section 15, it receives only in accordance with the informed consent form and, in any event,
will not collect, use, store, or disclose any PHI attached to or contained within the Subject Material in any manner that would
violate this Section of the Agreement.

 

Institution
acknowledges that, pursuant to Section 111 of the Medicare, Medicaid, and SCHIP Extension Act of 2007 (“MMSEA”), Sponsor
has an obligation to submit certain reports to the Centers for Medicare & Medicaid Services with respect to Medicare beneficiaries
who participate in the Study and experience a research injury for which diagnosis or treatment costs are incurred. Sponsor and
CRO recognize that each party is subject to laws and regulations protecting the confidentiality of research subject information.
Accordingly: (1) Institution agrees upon prior written request to provide to Sponsor, or CRO as designated by Sponsor, certain
identifiable patient information required by MMSEA for Study subjects who are Medicare beneficiaries and incur medical costs in
association with a research injury and whose costs are reimbursed by Sponsor pursuant to this Agreement; and (2) Institution further
agrees to otherwise cooperate with Sponsor (and CRO as designated by Sponsor) to the extent necessary for Sponsor to meet its
MMSEA reporting obligations.

 

5.2.
CRO’s ability to review the Study subjects’ Study-related information contained in the Study subject’s medical
record shall be subject to reasonable safeguards for the protection of Study subject confidentiality and the Study subjects’
informed consent form or HIPAA authorization form.

 

5.3.
Neither CRO, nor Sponsor through its agreement with CRO, shall attempt to identify, or contact, any Study subject unless permitted
by the informed consent form.

 

6.
Record Retention

 

As
applicable by law, Institution shall retain and preserve a copy of the Study records for the longer of:

 

	 	a)
    	two
    (2) years after a marketing authorization for Study Drug, or Study Device has been approved for the indication for which it
    was investigated or Sponsor has discontinued research on the Study Drug or Study Device;

 

    	5

    	 

    

 

	 	b)
    	such
    longer period as required by federal regulatory requirements; or
	 	 	 
	 	c)
    	as
    requested by Sponsor at Sponsor’s reasonable storage expense.

 

7.
Monitoring and Auditing

 

7.1.
Site visits by Sponsor, CRO and/or another authorized designee (e.g., Study monitor) will be scheduled in advance for times mutually
acceptable to the Parties during normal business hours. Sponsor’s, CRO’s and/or authorized designee’s access
is subject to reasonable safeguards to ensure confidentiality of medical records and systems. Sponsor and/or its authorized designee
must comply with Institution’s visitor rules when on site at Institution.

 

7.2.
Upon becoming aware of an audit or investigation by a regulatory agency with jurisdiction over the Study, Institution agrees to
provide Sponsor with prompt notice of the auditor investigation. If legally permissible or allowable by the regulatory agency
and permissible in accordance with the Institution’s policy, Sponsor may be available or request to be present with approval
from auditor during such audit, but Sponsor will not alter or interfere with any documentation or practice of Institution. Institution
shall be free to respond to any regulatory agency inquiries and will provide Sponsor with a copy of any formal response or documentation
to the regulatory agency regarding the Study.

 

8.
Inventions, Discoveries and Patents

 

8.1.
It is recognized and understood that certain existing inventions and technologies, and those arising outside of the research conducted
under this Agreement, are the separate property of Sponsor or Institution and are not affected by this Agreement, and neither
Sponsor nor Institution shall have any claims to or rights in such separate inventions and technologies.

 

8.2.
Any new patentable inventions, developments, or discoveries made during and in the performance of the Study (“Inventions”)
shall be promptly disclosed to Sponsor. Title to Inventions that necessarily use or necessarily incorporate Sponsor’s Study
Drug and/or Study Device shall reside with Sponsor (“Sponsor Inventions”). Institution shall assign all Sponsor Inventions
to Sponsor in writing. Institution shall, as reasonably requested by Sponsor, render reasonable assistance to the Sponsor in the
filing and prosecution of any United States and foreign counterpart part applications in regards to the Sponsor Inventions and
otherwise perfecting Sponsor’s rights in the Sponsor Inventions. Sponsor shall provide reasonable compensation to the Institution
for the time devoted to such activities and reimburse Institution for all reasonable expenses in regards to such activities. Institution
shall assign all Sponsor Inventions to Sponsor in writing. Title to Inventions other than Sponsor Inventions (“Other Inventions”)
shall reside with Sponsor if Sponsor personnel are the sole inventors, with Institution if Institution personnel are the sole
inventors, and shall be held jointly if both Institution and Sponsor personnel are inventors. Inventorship will be determined
in accordance with the principles of United States patent law, regardless of whether the Invention is patentable. The Institution
shall have the sole and exclusive right to obtain patent protection in the United States and foreign countries on any Other Inventions
to which it owns sole or joint title. During the Option Period (as defined below), Sponsor may request and Institution shall,
at Sponsor’s expense, file a patent application in regard to an Other Invention to which Institution owns sole or joint
title. Institution’s obligations under Sections 8.2 and 8.3 hereunder shall be performed by its appropriate office with
technology transfer responsibilities, if required by and in accordance with Institution’s policies.

 

    	6

    	 

    

 

8.3.
To the extent that Institution owns sole or joint title in any such Other Inventions, Sponsor is hereby granted, without option
fee other than consideration of the Study sponsored herein and the reimbursement to Institution for patent expenses incurred prior
to or during the option period, an option to acquire an exclusive, worldwide, royalty-bearing license to Institution’s rights
to any Other Invention, which option shall extend for no more than ninety (90) days after Sponsor’s receipt of an Invention
disclosure from Institution (“Option Period”). Sponsor and Institution shall use their reasonable efforts to negotiate,
for a period not to exceed ninety (90) days after Sponsor’s exercise of such option, a license agreement satisfactory to
both parties (“Negotiation Period”). Any such license agreement will include reimbursement to Institution for costs
of filing, prosecuting and maintaining any patent or other intellectual property application related to the Inventions. In the
event Sponsor fails to exercise its option within the Option Period, or Sponsor and Institution fail to reach agreement on the
terms of such license within the Negotiation Period, Institution shall have no further obligation to Sponsor under this Agreement
with regard to the specific Other Invention. Sponsor shall keep Institution fully informed, on at least an annual basis, as to
the commercial development of any Other Inventions to which Institution has joint title (the “Annual Joint Invention Report”).
If the Other Invention to which Institution has joint title is licensed, sublicensed, assigned or otherwise transferred to a party
by Sponsor or Sponsor receives any compensation, fees, royalties or other consideration in regards to the commercialization of
such Other Invention, Institution shall be entitled to share in the compensation or fees received by Sponsor on terms to be negotiated
by Institution and Sponsor (“Joint Revenue”). If within the Option Period, Sponsor desires an Exclusive License to
Institution’s rights in such Other Invention, then Sponsor shall exercise this option during the Option Period and if an
Exclusive License is executed, there shall be no Annual Joint Invention Report, or Joint Revenues and the terms of the Exclusive
License shall control.

 

8.4.
Nothing contained in this Agreement shall be deemed to grant either directly by implication, estoppel, or otherwise any
license under any patents, patent applications, or other proprietary interest to any other inventions, discovery or
improvement of either Sponsor or Institution.

 

8.5.
CRO and Institution agree that the provisions of this Agreement are intended to be interpreted and implemented so as
to comply with all applicable federal laws, rules, and regulations, including without limitation the requirements of Rev.
Proc. 2007-47; provided, however, if it is determined by the Internal Revenue Service or any other federal agency
or instrumentality (the “Government”) that the provisions of this Agreement are not in such compliance, then
those parties agree to modify the provisions and the implementation of this Agreement so as to be in compliance with all
applicable federal laws, rules, and regulations as determined by the Government.

 

8.6
Any license granted or ownership right assigned to Sponsor shall be subject to Institution’s royalty-free, irrevocable right
to use and permit other non-profit organizations to use Inventions and Other Inventions for educational and research purposes
and patient care, and, if applicable, to the rights of the United States government reserved under Public Laws 96-517, 97-256
and 98-620, codified at 35 U.S.C. 200-212, and any regulations issued thereunder.

 

9.
Publication

 

9.1.
Institution shall be free to publish, present, or use any Data and results arising out of its performance of the Protocol (individually,
a “Publication”). At least thirty (30) days prior to submission for Publication, Institution shall submit to Sponsor
for review and comment any proposed oral or written Publication (“Review Period”). Institution will consider any such
comments in good faith but is under no obligation to incorporate Sponsor’s suggestions. The Review Period for abstracts
or poster presentations shall be thirty (30) days. If during the Review Period, Sponsor notifies Institution in writing that:
(i) it desires patent applications to be filed on any inventions disclosed or contained in the disclosures, Institution will defer
Publication for a period not to exceed sixty (60) days, to permit Sponsor to file any desired patent applications; and (ii) if
the Publication contains Sponsor’s Confidential Information as defined in Section 3 and Sponsor requests Institution in
writing to delete such Sponsor’s Confidential Information, the Institution agrees to delete such Sponsor’s Confidential
Information only to the extent such deletion does not preclude the complete and accurate presentation and interpretation of the
Study results.

 

    	7

    	 

    

 

9.2.
The Parties agree that this Study is a multi-center clinical trial. Therefore, Institution agrees that the first Publication of
the results of the Study shall be made in conjunction with the presentation of a joint multi-center Publication of the Study results
with the Principal Investigators from all sites contributing Data, analyses, and comments. However, Institution may publish the
Data and Study results individually in accordance with this Section 9 upon first occurrence of one of the following: (i) multi
center Publication is published; (ii) no multi-center publication is submitted within eighteen (18) months after conclusion, abandonment,
or termination of the Study at all sites; or (iii) Sponsor confirms in writing there will be no multi-center Publication.

 

9.3.
If no multi-center Publication occurs within eighteen (18) months of the completion of the Study at all sites, upon request by
Institution, Sponsor will provide such Institution access to the aggregate Data from all Study sites.

 

9.4.
If the Institution, through its Principal Investigator, is identified to participate in the multi center Publication: (i) Institution
will have the opportunity to review the aggregate multi-center Data, upon request; and (ii) consistent with the International
Committee of Medical Journal Editors (ICMJE) regulations, Institution will have adequate opportunity to review and provide input
on any abstract or manuscript prior to its submission for Publication. Institution also retains the right, on behalf of its Principal
Investigator, to decline to be an author on any Publication.

 

10.
Use of Name

 

10.1.
Neither Institution nor CRO may use the name, trademark, logo, symbol, or other image or trade name of the other Party or their
employees and agents in any advertisement, promotion, or other form of publicity or news release or that in any way implies endorsement
without the prior written consent of an authorized representative of the other Party whose name is being used. Such approval will
not be unreasonably withheld.

 

10.2.
Institution and Sponsor understand that the amount of any payment made hereunder may be disclosed and made public by the other
party as required by law or regulation, including the Patient Protection and Affordable Care Act of 2010, provided that the disclosure
clearly designates the payment as having been made to Institution for research and not to the physician.

 

10.3.
Institution may acknowledge the Sponsor’s support, including but not limited to financial support as may be required by
academic journals, professional societies, funding agencies, and applicable regulations. Notwithstanding anything to the contrary
in this Agreement, Institution may publicly post information about the Study on Institution’s clinical trials directory/website.
Additionally, notwithstanding anything herein to the contrary, Institution shall have the right to post Sponsor’s and/or
CRO’s names, the Study title, and the Study period, and funding amount, on Institution publicly accessible lists of research
conducted by the Institution.

 

    	8

    	 

    

 

11.
Indemnification and Limitation of Liability

 

11.1
Sponsor’s indemnification obligations are outlined in a separate Letter of Indemnification, attached hereto as Exhibit
D.

 

11.2.
CRO expressly disclaims any liability in connection with the Study Drug or Study Device, including any liability for any claim
arising out of a condition caused by or allegedly caused by any Study procedures associated with such product except to the extent
that such liability is caused by the negligence, willful misconduct or breach of this Agreement by CRO.

 

11.3.
Institution shall have no obligation to indemnify CRO and CRO shall have no obligation to indemnify Institution.

 

12.
Subject Injury

 

Sponsor’s
subject injury obligations are outlined in Exhibit D.

 

13.
Insurance

 

13.1.
Institution shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the level of at
least $1,000,000 per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed in this Agreement.
However, if Institution is a public entity entitled to governmental immunity protections under applicable state law, then Institution
may provide liability coverage in accordance with any limitations associated with the applicable law.

 

13.2.
CRO shall maintain an insurance policy or a program of self-insurance at levels sufficient to support its obligations assumed
herein.

 

13.3.
Upon written request, either Party will provide evidence of its insurance or self-insurance acceptable to the other Party. A Party’s
inability to meet its insurance obligation constitutes material breach of this Agreement.

 

14.
Term and Termination

 

14.1.
This term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties’ Study-related
activities under the Agreement, unless terminated early as further described in this Section.

 

14.2.
Institution or CRO has the right to terminate this Agreement upon thirty (30) days prior written notice to the other Party. This
Agreement may be terminated immediately at any time for any reason by the Institution or CRO when, in their judgment or that of
the Principal Investigator, the Institution’s IRB, Scientific Review Committee, if applicable, or the Food and Drug Administration,
it is determined to be inappropriate, impractical, or inadvisable to continue, in order to protect the Study subjects’ rights,
welfare, and safety, or the IRB otherwise disapproves the Study. If for any reason Principal Investigator becomes unavailable
to direct the performance of the work under this Agreement, Institution shall promptly notify CRO. If the Parties are unable to
identify a mutually acceptable successor, this Agreement may be terminated by either Party upon thirty (30) days written notice.

 

    	9

    	 

    

 

14.3.
Notwithstanding the above a Party may, in addition to any other available remedies:

 

	 	a)
    	immediately
    terminate this Agreement upon the other Party’s material failure to adhere to the Protocol, except for deviation required
    to protect the rights, safety, and welfare of Study subjects; and/or
	 	 	 
	 	b)
    	terminate
    this Agreement upon the other Party’s material default or breach of this Agreement, provided that the defaulting/breaching
    Party fails to remedy such material default, breach, or failure to adhere to the Protocol within thirty (30) business days
    after written notice thereof.

 

14.4.
In addition to the above, this Agreement may be terminated by Institution in the event of a material default or breach of this
Agreement by CRO, or by CRO in the event of a material breach of this Agreement by Institution, provided that the defaulting/breaching
party fails to remedy such material default or breach within thirty (30) business days after written notice thereof.

 

14.5.
In the event that this Agreement is terminated prior to completion of the Study, for any reason, Institution shall:

 

	 	a)
    	notify
    the IRB that the Study has been terminated;
	 	 	 
	 	b)
    	cease
    enrolling subjects in the Study;
	 	 	 
	 	c)
    	cease
    treating Study subjects under the Protocol as directed by CRO to the extent medically permissible and appropriate;
	 	 	 
	 	d)
    	terminate,
    as soon as practicable, all other Study activities; and
	 	 	 
	 	e)
    	furnish
    to CRO any required final report for the Study in the form reasonably acceptable to CRO.

 

Promptly
following any such termination, Institution will provide to CRO copies of Data collected pursuant to the Study Protocol. Upon
Sponsor’s or CRO’s written request, Institution shall provide to the requesting party, at Sponsor’s or CRO’s
expense, all Sponsor’s Confidential Information provided under this Agreement provided, however, that Institution may retain
such copy of Confidential Information for record keeping purposes, monitoring its obligations, and exercising its rights hereunder,
subject to Institution’s ongoing compliance with the confidentiality and non-use obligations set forth in this Agreement.

 

14.6.
If this Study is terminated early by either Party, the Institution shall be reimbursed for all work completed, on a pro rata basis,
and reasonable costs of bringing the Study to termination incurred through the date of termination, and for non-cancelable commitments
properly incurred through that date. Upon receipt of notice of termination, Institution will use reasonable efforts to reduce
or eliminate further costs and expenses and will cooperate with CRO to provide for an orderly wind-down of the Study.

 

14.7.
Subsections 1.4, 1.6, and 14.6, and Sections 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (and the attached Letter of Indemnification), 12,
13, 15, 19 and 23, shall survive any termination or expiration of this Agreement, except that Section 3 shall survive for the
period stated in Section 3.1. Any provision of this Agreement that by its nature and intent remains valid after termination will
survive termination.

 

    	10

    	 

    

 

15.
Subject Material

 

15.1.
Subject Material means any biologic material of human origin including, without limitation, tissues, blood, plasma, urine, spinal
fluid, or other fluids derived from the Study subjects in accordance with and pursuant to the Protocol (“Subject Material”).

 

15.2.
Institution agrees to make the Subject Material available to the Sponsor in accordance with the Protocol for the purposes of the
Study. The Subject Material may be used by the Sponsor, central lab, or other contracted party only as allowed by the Study subject’s
informed consent form or pertinent institutional review board(s). Sponsor’s use of Subject Materials, other than as allowed
by the Study subject’s informed consent form, will require additional IRB review and approval.

 

16.
Subcontract

 

If
applicable, Institution has the right to subcontract to other sites to conduct the Study in accordance with the Protocol with
terms consistent with this Agreement with written approval of the Sponsor, which approval shall not be unreasonably withheld.
If Institution subcontracts any Study related duties, Institution shall contract with such subcontractors incorporating terms
substantially similar to the terms herein. Such subcontracts may be provided to the CRO upon written request.

 

The
Parties acknowledge and agree that the Sponsor and each of its affiliates is a third-party beneficiary to this Agreement.

 

17.
Notices

 

Any
notice, authorization, approval, consent or other communication will be in writing and deemed given:

 

	 	a)
    	Upon
    delivery in person;
	 	b)
    	Upon
    delivery by courier;
	 	c)
    	Upon
    delivery date by a nationally-recognized overnight delivery service such as FedEx.

 

If
to CRO:

 

Cancer
Insight, LLC

Attn:
Steven White

Chief
Operating Officer

110
E. Houston St.

San
Antonio, TX 78205

210-884-0810

swhite@cancerinsight.com

 

If
to Sponsor:

 

BriaCell
Therapeutics Corp.

820
Heinz Avenue

Berkeley,
CA 94710

Tel:
1-888-485-6340

Fax:
424-245-3719

 

    	11

    	 

    

 

If
to Institution:

 

Thomas
Jefferson University

Office
of Research Administration

125
S. 9th Street, Second Floor Sheridan,

Philadelphia,
PA 19107

Attn:
Director, JCRI Business Operations

 

With
a copy to Principal Investigator:

 

Thomas
Jefferson University

Saveri
Bhattacharya, DO

Jefferson
Medical College Building

Room
700

Philadelphia,
PA 19107

 

18.
Independent Contractor

 

It
is mutually understood and agreed that the relationship between Institution and CRO is that of independent contractors. No party
shall represent itself as the agent, employee, partner, joint venturer, or servant of the other. Except as specifically set forth
herein, no party shall have nor exercise any control or direction over the methods by which the other party performs work or obligations
under this Agreement. Further, nothing in this Agreement is intended to create any partnership, joint ventures, lease, or equity
relationship, expressly or by implication, among those parties.

 

19.
Clinical Trial Registry

 

Prior
to enrollment of the first subject in the Study, Sponsor will register the Study on www.clinicaltrials.gov in accordance with
the requirements of the International Committee of Medical Journal Editors (ICMJE) and Public Law 110-85. Results of this Study
will be reported in compliance with applicable laws.

 

20.
Non-Referral/ Anti-Corruption Language

 

20.1.
Institution and CRO, on behalf of Sponsor, agree that it is not their intent under this Agreement to induce or encourage the unlawful
referral of subjects or business between the Parties, and there shall not be any requirement under this Agreement that those parties,
their employees or affiliates, including their medical staff, engage in any unlawful referral of subjects to, or order or purchase
products or services from, one of those parties.

 

20.2.
Institution and CRO, on behalf of Sponsor, agree that their employees, who are involved in the conduct of the Study, will not
offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and shall not make or cause another to
make any offer or payment to any individual or entity for the purpose of influencing a decision for the benefit of one of those
parties.

 

21.
Force Majeure

 

If
either Party hereto shall be delayed or hindered in, or prevented from, the performance of any act required hereunder for any
reason beyond such Party’s direct control, including but not limited to, strike, lockouts, labor troubles, governmental
or judicial actions or orders, riots, insurrections, war, acts of God, inclement weather, or other reason beyond the Party’s
control (a “Disability”) then such Party’s performance shall be excused for the period of the Disability. Any
Study timelines affected by a Disability shall be extended for a period equal to the delay and any affected Budget shall be adjusted
to account for cost increases or decreases resulting from the Disability. The Party affected by the Disability shall notify the
other Party of such Disability as provided for herein.

 

    	12

    	 

    

 

22.
Counterparts

 

This
Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute
one and the same document, and is binding on all Parties notwithstanding that each of the Parties may have signed different counterparts.
Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered original signature unless prohibited
by applicable law.

 

23.
Debarment

 

The
Institution certifies that to its knowledge neither it, nor any of its employees, agents or other persons performing the Study
under its direction, is currently debarred, suspended, or excluded under the Federal Food, Drug and Cosmetic Act, as amended,
or disqualified under the provisions of 21 CFR §312.70. In the event that the Principal Investigator or any Study personnel
becomes debarred or disqualified during the term of this Agreement or within 1 year after termination of the Study, the Institution
agrees to promptly notify CRO after learning of such event. Institution certifies that it is not excluded from a federal health
care program, including Medicare and Medicaid. In the event an Institution becomes excluded during the term of this Agreement
or within 1 year after termination of the Study, the Institution agrees to promptly notify CRO after learning of such event.

 

24.
Choice of Law -Intentionally omitted

 

25.
Entire Agreement

 

Section
and clause headings are used herein solely for convenience of reference and are not intended as substantive parts of the Parties’
agreement. This ACTA incorporates the Exhibits referenced herein. This written ACTA constitutes the entire agreement between the
Parties concerning the subject matter, and supersedes all other or prior agreements or understandings, whether written or oral,
with respect to that subject matter. Any changes made to the terms, conditions or amounts cited in this ACTA require the written
approval of each Party’s authorized representative.

 

    	13

    	 

    

 

The
authorized representatives of the Parties have signed this ACTA as set forth below.

 

	Thomas
    Jefferson University	 	Cancer
    Insight, LLC
	 	 	 	 	 
	By:		 	By:	 
	Name:	Margaret
    Burwell	 	Name:	Steven
    White
	Title:
    	Associate
    Director, Preaward	 	Title:
    	COO
	 	 	 	 	 
	Date:
    	7/18/2018	 	Date:
    	July
    23, 2018

 

	READ
    AND ACKNOWLEDGE	 
	 	 
	By:		 
	Name:
    	Saveri
    Bhattacharya, DO	 
	Title
    : 	Principal
    Investigator 	 
	 	 	 
	Date:
    	7/15/19	 

 

    	14

    	 

    

 

EXHIBIT
A

PROTOCOL

 

See
attached and incorporated master Protocol, which is identified as Protocol BRI-ROL-001, and amendments thereto.

 

    	15

    	 

    

 

EXHIBITB

BUDGET

 

Fee
and Payment Schedule:

 

	 	A.
    	This
    Budget has been negotiated at fair and reasonable value. Institution has not been influenced to participate in this Study
    based on financial or other inducements from Sponsor. The compensation may be used at the discretion of Institution to offset
    the costs of the Study. For Study subject visit and Study conduct reimbursements, an item listed herein will be considered
    payable upon Institution’s complete and accurate data entry into the applicable electronic data capture system (EDC)
    of all assessments associated with that visit in the EDC.
	 	 	 
	 	B.
    	The
    compensation per Study subject will be earned by Institution and made payable by Cancer Insight as follows:

 

	 	i.
    	 	$2,100.00
    will be paid upon completion of the Baseline Visit, as defined by the Protocol;
	 	 	 	 
	 	ii.
    	 	$2,100.00
    will be paid upon completion of Cycle One, as defined by the Protocol;
	 	 	 	 
	 	iii.
    	 	$2,100.00
    will be paid upon completion of Cycle Two, as defined by the Protocol;
	 	 	 	 
	 	iv.
    	 	$2,100.00
    will be paid upon completion of Cycle Three, as defined by the Protocol;
	 	 	 	 
	 	v.
    	 	$2,100.00
    will be paid upon completion of Cycle Four, as defined by the Protocol;
	 	 	 	 
	 	vi.
    	 	$2,100.00
    will be paid upon completion of Cycle Five, as defined by the Protocol;
	 	 	 	 
	 	vii.
    	 	$2,100.00
    will be paid upon completion of Cycle Six, as defined by the Protocol;
	 	 	 	 
	 	viii.
    	 	$2,100.00
    will be paid upon completion of Cycle Seven, as defined by the Protocol;
	 	 	 	 
	 	ix.
    	 	$2,500.00
    will be paid upon completion of Cycle Eight, as defined by the Protocol;
	 	 	 	 
	 	x.
    	 	$2,100.00
    will be paid upon completion of Cycle Nine, as defined by the Protocol;
	 	 	 	 
	 	xi.
    	 	$2,100.00
    will be paid upon completion of Cycle Ten, as defined by the Protocol;
	 	 	 	 
	 	xii.
    	 	$2,500.00
    will be paid upon completion of Cycle Eleven, as defined by the Protocol;
	 	 	 	 
	 	xiii.
    	 	$2,100.00
    will be paid upon completion of Cycle Twelve, as defined by the Protocol;
	 	 	 	 
	 	xiv.
    	 	$2,100.00
    will be paid upon completion of Cycle Thirteen, as defined by the Protocol;
	 	 	 	 
	 	xv.
    	 	$2,100.00
    will be paid upon completion of Cycle Fourteen, as defined by the Protocol;
	 	 	 	 
	 	xvi.
    	 	$2,100.00
    will be paid upon completion of Cycle Fifteen, as defined by the Protocol;
	 	 	 	 
	 	xvii.
    	 	$2,100.00
    will be paid upon completion of Cycle Sixteen, as defined by the Protocol;
	 	 	 	 
	 	xviii.
    	 	$2,100.00
    will be paid upon completion of Cycle Seventeen, as defined by the Protocol;

 

    	16

    	 

    

 

	 	xix.
	 	$2,100.00
    will be paid upon completion of the End of Treatment visit, as defined by the Protocol.
	 	 	 	 
	 	xx.  	 	Additional
    cycles shall be invoiceable to Study sponsor in the amount of $2,100.00 per occurrence.

 

	 	C.
    	$1,500.00
    shall be paid for Study subject screen failure per occurrence. This amount shall be capped at five occurrences per calendar
    year. Any remaining balance of billable screen failure occurrences shall not carry over to subsequent calendar years. For
    purposes of this budget, a screen failure shall be defined as a potential Study subject who, during the process of active
    consideration for enrollment in the Study, did not meet one or more criteria required for participation in the Study.
	 	 	 
	 	D.
    	Where
    Institution utilizes Western IRB (“WIRB”) as their central IRB, Cancer Insight will pay for WIRB costs directly
    and Institution may direct WIRB to invoice Cancer Insight directly.
	 	 	 
	 	E.
    	Start-up
    funding will be provided in the amount of $7,000.00 and payable upon execution of the Agreement, which may be used at the
    discretion of Institution to offset the costs of the Study.
	 	 	 
	 	F.
    	A
    one-time Billing Compliance Fee will be paid in the amount of $3,500.00.
	 	 	 
	 	G.
    	A
    one-time Pharmacy Start-Up Fee will be paid in the amount of $1,700.00.
	 	 	 
	 	H.
    	A
    one-time Protocol Review Committee Fee will be paid in the amount of $1,000.00.
	 	 	 
	 	I.
    	A
    one-time Internal Review Committee Fee will be paid in the amount of $2,500.00.
	 	 	 
	 	J.
    	A
    Protocol Amendment Fee will be paid in the amount of $500.00 per occurrence.
	 	 	 
	 	K.
    	A
    monthly Pharmacy Maintenance Fee will be paid in the amount of $332.00. This amount shall be payable in the month the site
    initiation visit is performed and for each subsequent month thereafter until Institution is no longer participating in the
    Study and/or the Agreement is terminated.
	 	 	 
	 	L.
    	A
    one -time Pharmacy Close-Out Fee will be paid in the amount of $350.00.
	 	 	 
	 	M.
    	A
    one-time Record Retention Fee will be paid in the amount of $1,000.00.
	 	 	 
	 	N.
    	A
    one-time Close-Out Administration Fee will be paid in the amount of $1,500.00.
	 	 	 
	 	O.
    	Sponsor
    will provide pembrolizumab (KEYTRUDA®, anti-PD-1) and ipilimumab (YERVOY®, anti-CTLA-4), as
    applicable. Ipilimumab treatment is limited to four doses. For pembrolizumab, dosing may continue until disease progression,
    unacceptable toxicity, and/or up to twenty-four (24) months in Study subjects without disease progression.
	 	 	 
	 	P.
    	If
    provided by Institution, the cost of Pembrolizumab shall be invoiceable to Study sponsor in the amount of $12,750.00 per dose.
	 	 	 
	 	Q.
    	If
    provided by Institution, the cost of Ipilimumab shall be invoiceable to Study sponsor in the amount of $38,750.00 per dose.
	 	 	 
	 	R.
    	Sponsor
    will provide Interferon-Alpha, BriaVax, DTH (BriaTest), Anergy tests (Candin), and cyclophosphamide Study drugs. In the event
    any Protocol-required study drugs are provided by Institution through their pharmacy or other means, the cost of such shall
    be invoiceable by Institution and paid by Sponsor.

 

    	17

    	 

    

 

	 	S.
    	The
    cost of PET scans and CT scans shall be invoiceable to Study sponsor in the amount of $4,750.00 per occurrence.
	 	 	 
	 	T.
    	The
    cost of RECIST reads shall be invoiceable to Study sponsor in the amount of $250.00 per occurrence.
	 	 	 
	 	U.
    	Invoices
    shall be sent to Cancer Insight via email to Steven White at swhite@cancerinsight.com. In the event that such method of delivery
    is rendered impossible or impractical, invoices may be sent to Cancer Insight via mail to:
	 	 	 
	 	 	Cancer
    Insight, LLC 
	 	 	Attn:
    Steven R. White
	 	 	110
    East Houston Street, Floor 7 
	 	 	San
    Antonio, Texas 78205
	 	 	 
	 	V.
    	Payments
    shall be sent no later than thirty (30) days from receipt and approval of invoices. Payments will be issued via electronic
    funds transfer whenever possible and under the following instructions:
	 	 	 
	 	 	Bank
    Name:
	 	 	Account
    Number:
	 	 	Routing
    Number:
	 	 	 
	 	 	In
    the event that such method of payment is rendered impossible or impractical, payments will be issued via check and mailed
    to the address included on the associated invoice.

 

    	18

    	 

    

 

EXHIBIT
C

ADMINISTRATIVE
AND STUDY POINTS OF CONTACT

 

CRO
Clinical Department Point of Contact:

 

Karen
Arrington

karrington@cancerinsight.com

 

CRO
Regulatory Department Point of Contact:

 

Susie
Hargrove

shargrove@cancerinsight.com

 

CRO
Administrative and Billing Department Point of Contact:

 

Steven
White

swhite@cancerinsight.com

 

    	19

    	 

    

 

EXHIBIT
D

LETTER
OF INDEMNIFICATION (LOI)/SUBJECT INJURY

 

INSTITUTION:
THOMAS JEFFERSON UNIVERSITY (the “Institution”)

 

	TITLE
    OF CLINICAL TRIAL: 	“A
    Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent Breast Cancer Patients
    in Combination with lpilimumab or Pembrolizumab”

 

CRO:
Cancer Insight, LLC

 

STUDY
NUMBER: BRI-ROL-001

 

	1)
    	Institution
    has entered into an Accelerated Clinical Trial Agreement (ACTA) with CRO to participate in the above sponsored Study. CRO
    has been engaged by BriaCell Therapeutics Corp. (the “Sponsor”) to arrange and administer this BriaCell Therapeutics
    Corp. sponsored multi-center clinical trial.
	 	 
	2)
    	Sponsor
    has delegated to CRO responsibility for the management and monitoring of this Study. Sponsor has further authorized CRO to
    bind Sponsor to its obligations within the Accelerated Clinical Trial Agreement for this Study executed between CRO and Institution.
    Sponsor accepts responsibility for its obligations contained in that Accelerated Clinical Trial Agreement.
	 	 
	3)
    	Institution
    agrees to participate by allowing the Study to be undertaken utilizing such facilities, personnel and equipment as Institution
    may reasonably need for its conduct of the Study.
	 	 
	4)
    	In
    consideration of such participation by Institution, and subject to paragraph 5 below, the Sponsor shall defend, indemnify,
    and hold harmless the Institution and its medical affiliates and affiliated hospitals, and each of their trustees, officers,
    directors, governing bodies, subsidiaries, affiliates, investigators, employees, IRB members, agents, successors, heirs and
    assigns (collectively referred to as “Institution’s Indemnitees”), from and against any third party claims,
    loss, damage, cost and expense of claims (including reasonable attorney’s fees) and suits (“Claims”), alleged
    to be caused by or arising from the conduct of the Study or use of the Study Drug or Study Device under this Agreement or
    from the use of the Study results, regardless of the legal theory asserted.
	 	 
	5)
    	Sponsor
    shall have no obligation to provide such indemnification to the extent that such Claim is solely caused by Institution’s
    lndemnitee(s)’: (1) failure to adhere to and comply with all material and substantive specifications and directions
    set forth in the Protocol (except to the extent such deviation is reasonable to protect the rights, safety and welfare of
    the Study subjects); (2) failure to comply with all applicable laws and regulations in the performance of the Study; or (3)
    if such claim is directly caused by the negligent acts or omissions of Institution’s lndemnitees(s).
	 	 
	6)
    	Subject
    to the limits and without waiving any immunities provided under applicable law (including constitutional provisions, statutes
    and case law) regarding the status, powers and authority of the Institution or the Institution’s principal(s), Institution
    shall indemnify, hold harmless and defend Sponsor, its directors, officers, employees and agents, (“Sponsor’s
    Indemnitees”) from and against only those third-party Claims to the extent directly attributable to Institution’s
    negligence in its conduct of the Study. Notwithstanding the above, Institution shall have no obligation to indemnify Sponsor
    for any other Claims (including, but not limited to, infringement or product liability Claims).

 

    	20

    	 

    

 

	7)
    	The
    indemnified party shall give notice to the indemnifying party promptly upon receipt of written notice of a Claim for which
    indemnification may be sought under this Agreement, provided, however, that failure to provide such notice shall not relieve
    indemnifying party of its indemnification obligations except to the extent that the indemnifying party’s ability to
    defend such Claim is materially, adversely affected by such failure. Indemnifying party shall not make any settlement admitting
    fault or incur any liability on the part of the indemnified party without indemnified Party’s prior written consent,
    such consent not to be unreasonably withheld or delayed. The indemnified Party shall cooperate with indemnifying Party in
    all reasonable respects regarding the defense of any such Claim, at indemnifying Party’s expense. The indemnified Party
    shall be entitled to retain counsel of its choice at its own expense. In the event a Claim falls under this indemnification
    clause, in no event shall the indemnified Party compromise, settle or otherwise admit any liability with respect to any Claim
    without the prior written consent of the indemnifying Party, and such consent not to be unreasonably withheld or delayed.
	 	 
	8)
    	EXCEPT
    FOR THE PARTIES’ OBLIGATIONS TO INDEMNIFY EACH OTHER AS STATED ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY
    FOR SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE
    POSSIBILITY OF THE SAME.
	 	 
	9)
    	If
    a Study subject suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Institution, was directly
    caused by a Study Drug or Study Device or any properly performed procedures required by the Protocol, Sponsor shall reimburse
    for the reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization,
    but only to the extent such expenses are not attributable to: (i) Institution’s negligence or willful misconduct; or
    (ii) the natural progression of an underlying or pre-existing condition or events, unless exacerbated by participating in
    the Study.
	 	 
	10)
    	Sponsor
    shall, at its sole cost and expense, procure and maintain commercial general liability insurance, clinical trial insurance
    and products liability insurance or equivalent self-insurance, unless otherwise indicated in an attachment, in amounts not
    less than $5,000,000.00 per occurrence and $5,000,000.00 annual aggregate. Such commercial general liability insurance, clinical
    trial insurance and products liability insurance or equivalent self-insurance shall provide contractual liability coverage
    for Sponsor’s indemnification obligations herein.
	 	 
	11)
    	Upon
    written request, Sponsor will provide evidence of its insurance policy or a program of self insurance and will provide Institution
    with written notice of any material change in its coverage which would affect Sponsor’s ability to meet its obligations
    under this Agreement. Sponsor’s inability to meet its insurance obligation constitutes material breach of this LOI and
    the Accelerated Clinical Trial Agreement executed with the CRO for this Study.
	 	 
	12)
    	During
    the Study and for at least two (2) years following the completion of the Study at all sites, Sponsor shall promptly provide
    Institution and Principal Investigator with the written report of any findings, including Study results and any routine monitoring
    findings in site monitoring reports, and data safety monitoring committee reports including, but not limited to, data and
    safety analyses, and any Study information that may (i) affect the safety and welfare of current or former Study subjects,
    or (ii) influence the conduct of the Study. Institution and/or Principal Investigator will communicate findings to the IRB
    and Study subjects, as appropriate.

 

    	21

    	 

    

 

	13
    	Except
    as     permitted in Article 10.3 in the ACTA, neither Institution nor Sponsor may use the name, trademark, logo, symbol, or
    other     image     or trade name of any other party or their employees and agents in any advertisement, promotion, or other
    form of     publicity     or news release or that in any way implies endorsement without the prior written consent of an
    authorized     representative of     the other party whose name is being used. Such approval will not be unreasonably
    withheld.

 

The
authorized representatives have signed this Letter of Indemnification as set forth below.

 

	Thomas
    Jefferson University	 	BriaCell
    Therapeutics Corp.
	 	 	 	 	 
	By:		 	By:	
	Name:	Margaret
    Burwell	 	Name:	William
    V. Williams
	Title:
    	Associate
    Director, Preaward	 	Title:
    	President
    and CEO
	 	 	 	 	 
	Date:
    	7/18/2018	 	Date:
    	2018
    July 23

 

	READ
    AND ACKNOWLEDGE	 
	 	 
	By:		 
	Name:
    	Saveri
    Bhattacharya, DO	 
	Title
    : 	Principal
    Investigator 	 
	 	 	 
	Date:
    	7/18/2018	 

 

    	22EXECUTIVE
EMPLOYMENT AGREEMENT

 

THIS
AGREEMENT, entered into and made effective this 12th day of October, 2016,

 

BETWEEN:

 

BriaCell
Therapeutics Corp., a company incorporated under the laws of Delaware and having its office at 820 Heinz Avenue, Berkeley,
CA, USA, 94710

 

(the
“Company”)

 

AND:

 

Dr.
William V. Williams, an individual residing at 620 South Eagle Road, Havertown, PA 19083

(the
“Executive”)

 

WHEREAS
the Company wishes to employ the Executive as President and Chief Executive Officer of the Company and the Executive
now wish to continue this relationship and formalize the terms of employment (the “Employment”) on the terms
and conditions hereinafter set forth,

 

AND
WHEREAS the Executive will commence employment with the Company on the 31st day of October, 2016,

 

AND
WHEREAS on or about November 2014, Ansell Capital Corp which was renamed BriaCell Therapeutics Corp (“Parent Company”)
acquired all of the issued and outstanding securities of the Company and the Company has become a wholly-owned subsidiary
of the Parent Company, which is publically traded on the Toronto Stock Exchange Venture (“TSX-V’’).

 

In
consideration of the mutual covenants and agreements contained herein the parties hereto covenant and agree as follows:

 

	1.	ENGAGEMENT

 

	1.1	The
    term of this Agreement and the employment of the Executive (the “Period of Engagement”) shall be for one
    (1) year provided that:

 

	 	(a)	the
    Company may terminate this Agreement and the Employment at any time as set out in Section 7 hereof; and
	 	 	 
	 	(b)	the
    Executive may terminate this Agreement and the Employment at any time as set out in Section 7.1(e).
	 	 	 
	 	(c)	If
    the Period of Engagement is not terminated or a new contract is not entered into upon its expiration, this Agreement shall
    continue in full force and effect, and may be terminated by either party on no less than thirty (30) days’ advance written
    notice.

 

    	 	 	 

    	 	-2-	 

    

 

	2.	DUTIES

 

	2.1	The
    Executive will be responsible for performing those duties that are customarily performed by a chief executive officer for
    a public company with its shares listed on a recognized exchange in Canada or elsewhere, at the direction of the Board of
    Directors of the Parent Company (the “Board”), which will include but are not limited to the duties set
    out in Schedule “A”.
	 	 
	2.2	The
    Executive acknowledges and agrees that, in the course of carrying out, performing and fulfilling his duties under this Agreement,
    the Executive will be acting in a fiduciary capacity and will owe fiduciary obligations towards the Company during the period
    of his employment and for a reasonable period of time following the termination of his employment for any reason.
	 	 
	2.3	Except
    as described in the following provisions of this Section 2.3, the Executive will faithfully perform those duties and responsibilities
    and will devote his full working time and use his best efforts to advance the business and welfare of the Company and its
    subsidiaries in furtherance of the policies established by the Board. The Company acknowledges that the Executive has a continuing
    short-term obligation, which will be concluded within the next six (6) months, to lncyte corporation related to the US FDA
    approval of Baricitinib. The Executive, at his discretion, will be permitted to complete his commitment to lncyte and manage
    his time in connection with that commitment, while faithfully performing his duties and responsibilities to the Company. Except
    for the above stated commitment to lncyte, the Executive represents and warrants that the Executive is not subject to any
    constraints which would prevent the Executive from continuing to be employed by the Company and from devoting the Executive’s
    full time and attention to the affairs of the Company.
	 	 
	2.4	The
    Executive’s initial reporting location will be at the Company’s offices listed in the preamble, unless otherwise
    designated by the Board. The Executive will conform to all lawful instructions and directions from time to time given to him
    by the Board. During the Period of Engagement, except as described in Section 2.3 above, the Executive will not engage in
    any other employment activities with any other Company or other entity or person for any direct or indirect remuneration without
    the express written consent of the Board of the Company.
	 	 
	2.5	During
    the Period of Engagement, Executive shall receive a seat on the Board and shall be entitled to engage in discussion with fellow
    Board Members and vote on such items as allowed by the corporate documents of the Parent Company, provided however, the Board
    may preclude Executive from voting on any matter considered a conflict of interest.
	 	 
	3.	COMPENSATION

 

	3.1	Base
    Fee. During the initial twelve (12) months of the Period of Engagement, the Company shall pay the Executive an starting
    total base fee salary (the “Base Fee”) at the rate of USD $175,000 per year, less deductions required by
    law, payable semi-monthly on the 15th and last day of each month or such other schedule as determined by the Board, but no
    less than semi-monthly. If
    the Period of Engagement extends beyond twelve (12) months, on not less than an annual basis, the Company shall review the
    Executive’s Base Fee and make such adjustments commensurate with the progress of the Company in achieving its business
    objectives.
	 	 
	3.2	Stock
    Based Compensation. In addition to the Base Fee, the Executive shall be entitled to participate in the Parent Company’s
    stock option plan, as more particularly described in the Stock Option Grant and related documents. The Executive will receive
    an initial 632,000 options priced at the market price as of the date of the execution of this Agreement.

 

    	 	 	 

    	 	-3-	 

    

 

	3.3	Milestone-Based
    Bonuses.
    In the event that Company, under
    Executive’s leadership, is successful in reaching those certain milestones listed on Exhibit A, Company shall pay Executive
    bonuses in such amounts as listed on Exhibit A, on or before the dates set forth in such Exhibit A.
	 	 
	4.	BENEFITS
	 	 
	4.1	During
    the Period of Engagement the Company will offer to the Executive, the right to participate in all benefit programs maintained
    by the Company that are available to its senior executives. Participation in these benefits will be subject to the terms of
    the applicable plans. The Company may change these terms from time to time, in which case the Company will advise the Executive
    of the change(s). Participation in the benefit programs shall terminate on the Executive’s Date of Termination (as defined
    herein) and the Executive shall not be entitled to any benefits or compensation on account of benefits after his Date of Termination
    date except as otherwise set out in Sections 7 and 8 herein.
	 	 
	5.	EXPENSES
	 	 
	5.1	The
    Company will pay or reimburse the Executive for such reasonable travel, entertainment or other business expenses as may be
    incurred on behalf of the Company during the Period of Engagement in connection with the performance of his duties hereunder,
    but only to the extent that such expenses were either specifically authorized by the Company or incurred in accordance with
    policies established by the Board and provided that the Executive shall furnish the Company with such evidence relating to
    such expenses as the Company may reasonably require to substantiate such expenses for tax purposes. The Company will not reimburse
    the Executive for any expenses incurred during the periods when the Executive is or was not actively employed.
	 	 
	6.	VACATION
	 	 
	6.1	During
    the initial twelve (12) months of the Period of Engagement and for each twelve (12) consecutive month period thereafter, the
    Executive shall be entitled to an annual paid vacation that is not less than an aggregate of fifteen (15) business days per
    calendar year at a time or times which may be reasonably satisfactory to the Executive and the Board of the Company. Vacation
    pay is included in the Executive’s Base Fee.
	 	 
	7.	TERMINATION
    OF ENGAGEMENT
	 	 
	7.1	Circumstances
    of Termination. Notwithstanding the terms set forth in Section 1 hereof, the Executive’s engagement shall terminate
    under any of the following circumstances:

 

	 	(a)	Death.
    In the event of the Executive’s death.
	 	 	 
	 	(b)	Permanent
    Disability. At the option of the Company, because the Executive becomes physically or mentally incapacitated or disabled
    so that:

 

	 	(i)	he
    is unable to perform for the Company substantially the same services as he performed prior to incurring such incapacity or
    disability or to devote his full working time or use his best efforts to advance the business and welfare of the Company or
    otherwise to perform his duties under this Agreement; and

 

    	 	 	 

    	 	-4-	 

    

 

	 	(ii)	such
    condition exists for an aggregate of six (6) months in any twelve (12) consecutive calendar month period;

 

	 	 	the
    Company, at its option and expense, being entitled to retain a physician reasonably acceptable to the Executive to confirm
    the existence of such incapacity or disability, and the determination of such physician being binding upon the Company and
    the Executive (“Permanent Disability”).

 

	 	(c)	Cause.
    At the option of the Company upon the occurrence of any action by the Executive as set forth below (“Cause”).
    Cause shall mean but not be limited to:

 

	 	(i)	entering
    a guilty plea or being convicted (without a subsequent pardon) for the following offences:

 

	 	(A)	a
    misdemeanor conviction or indictable offense under the laws of Canada or United States;
	 	 	 
	 	(B)	a
    quasi-criminal offence (for example relating to tax, immigration, drugs, firearms, money laundering or securities legislation)
    of Canada or the United States or any other jurisdiction which has an equivalent offence;
	 	 	 
	 	(C)	or
    a felony under the criminal legislation of Canada or the United States of America, or any state or territory therein or an
    offence under the criminal legislation of any other jurisdiction which has an equivalent offence;

 

	 	(ii)	engaging
    in serious misconduct or gross negligence while carrying out the Executive’s duties under this Agreement, resulting,
    in either case, in material harm to the condition or reputation of the Company and its subsidiaries (considered on an aggregate
    basis);
	 	 	 
	 	(iii)	the
    breach of Sections 9.1 to 9.5 of this Agreement;
	 	 	 
	 	(iv)	the
    failure to substantially perform the services to be rendered by the Executive hereunder (except in the event of the Executive’s
    disability) after receipt of written notice from the Board and a reasonable opportunity (but in no event more than fifteen
    (15) days after notice was delivered) for the Executive to cure such non-performance; or
	 	 	 
	 	(v)	the
    failure to adhere to, or take affirmative steps to carry out, any legal and proper directive of the Board, after receipt of
    written notice from the Board and a reasonable opportunity (but in no event more than fifteen (15) days after notice was delivered)
    to cure such non-adherence or failure to act.

 

    	 	 	 

    	 	-5-	 

    

 

	 	(d)	Not
    for Cause. At the option of the Board, at any time for any reason other than those referred to above or for no reason
    at all; whereupon the Company shall become obligated to make only those payments set forth in Section 8.l(d) hereof.
	 	 	 
	 	(e)	On
    Notice. At the option of the Executive on providing to the Company thirty (30) days prior written notice in accordance
    with Section 7.2.

 

	7.2	Notice
    of Termination. Any termination of the Executive’s engagement by the Company or the Executive (other than termination
    pursuant to Section 7.l(a) hereof) shall be communicated by written Notice of Termination in accordance with Section 10.1.
    For purposes of this Agreement, a “Notice of Termination” shall mean a notice terminating the Executive’s
    engagement by either party. If a Notice of Termination is given by the Company or the Executive, such notice shall indicate
    the specific termination provision in this Agreement relied upon and shall set forth in reasonable detail the facts and circumstances
    that provide a basis for termination of the Executive’s engagement under the provision so indicated. For purposes of
    this Agreement, the “Date of Termination” shall be the date on which the Executive ceases to actively perform
    services for the Company and shall not include any period in which the Executive is paid or awarded salary in lieu of termination,
    including any period of notice or severance required by any applicable statute or common law.

 

	8.	PAYMENTS
    UPON TERMINATION OF ENGAGEMENT
	 	 
	8.1	Payments.
    The     Period of Engagement shall expire as of the Date of Termination.

 

	 	(a)	If
    the Company terminates the Executive’s engagement for Cause or if the Executive voluntarily terminated his engagement
    in accordance with Section 7.l(e), the Company’s obligation to compensate the Executive shall in all respects cease
    as of the Date of Termination, except that the Company shall pay the Executive the Base Fee accrued under Section
    3.1
    and the reimbursable expenses incurred under Section 5.1 of this Agreement up to such Date of Termination (the
    “Accrued     Obligations”);
	 	 	 
	 	(b)	If
    the Executive’s engagement is terminated due to the death of the Executive, the Company’s obligation to compensate
    the Executive shall in all respects cease as of the Date of Termination, except that within thirty (30) days after the Date
    of Termination the Company shall pay the Executive the Accrued Obligations;
	 	 	 
	 	(c)	If
    the Executive’s engagement is terminated upon the Permanent Disability of the Executive, the Company’s obligation
    to compensate the Executive shall in all respects cease as of the Date of Termination, except that within thirty {30) days
    after the Date of Termination the Company shall pay the Executive the Accrued Obligations;
	 	 	 
	 	(d)	If
    the Executive’s engagement is terminated by the Company pursuant to Section 7.l(d), the Company’s obligation to
    compensate the Executive shall in all respects cease, except that within 30 days after the Date of Termination the Company
    shall pay the Executive the Accrued Obligations and the Company shall pay to the Executive a lump sum termination fee equal
    to the then current monthly salary of Executive times the number of complete months that Executive has been employed by the
    Company up to the Date of Termination ( up to a maximum of 12) divided by two.

 

    	 	 	 

    	 	-6-	 

    

 

	 	(e)	If
the Executive’s engagement is terminated by Company prior to reaching any of the milestone bonuses listed on Exhibit A,
such milestone shall expire and Executive shall not be entitled to any bonus for reaching same. Should any such milestone be reached
prior to the termination of Executive, Company shall pay such bonus no later than the Date of Termination.
	 	 	 
	 	(f)	If
    the Executive’s engagement is terminated pursuant to Section 7.1, any un exercised stock options granted to the Executive
    will terminate in accordance with the provisions of the Parent Company’s stock option plan and the stock option agreement(s)
    between the Parent Company and the Executive in connection therewith.

 

	8.2	Release
    and Satisfaction. The Executive agrees that the payment by the Company of the amounts provided under Section 8.1
    hereof will fully satisfy all of his statutory, contractual and common law entitlements for notice, termination pay, severance
    pay and pay in lieu of notice. With respect to the Executive, the Executive and his respective heirs, successors and assigns,
    upon payment by the Company of the amounts provided under Section 8.1 hereof and the faithful performance by the Company of
    all of its other obligations under this Agreement, shall release, relinquish and forever discharge the Company and
    its subsidiaries,
    any director, officer, employee, shareholder or agent of the Company and its subsidiaries from any and all claims, damages,
    losses, costs, expenses, liabilities or obligations, whether known or unknown, arising from the Executive’s hiring,
    employment or termination of employment. As a condition for making any payments provided under Section 8 hereof, the Company
    may (but need not) require the Executive to execute a release reconfirming its agreement with the provisions of this Section
    8.2.
	 	 
	8.3	Effect
    on this Agreement. Any termination of the Executive’s engagement and any expiration of the Period of Engagement
    under this Agreement shall not affect the continuing operation and effect of Sections 8.2,
    9.1,
    9.2,
    9.4,, 9.4, 9.5 and 9.7 hereof, which shall continue in full force and effect with respect to the Company and the Executive,
    and their respective heirs, successors and assigns. Nothing in Section 8.1 hereof shall be deemed to operate or shall operate
    as a release, settlement of discharge of any liability to the Company or others from any action or omission by the Executive
    enumerated in Section 7.l(c) hereof as a possible basis for termination of the Executive’s engagement for Cause.
	 	 
	9.	NON-DISCLOSURE
    AND NON-SOLICITATION
	 	 
	9.1	Confidential
    Information.

 

	 	The
    Executive agrees to act diligently, loyally and in a trustworthy manner to the best of his knowledge, skill and ability. At
    all times, the Executive shall act in the best interest of the Company.
	 	 
	 	The
    Executive acknowledges and agrees that, in the course of carrying out, performing and fulfilling his duties under this Agreement,
    the Executive will be acting in a fiduciary capacity and will have access to and will be entrusted with Confidential Information
    (as defined herein).

 

    	 	 	 

    	 	-7-	 

    

 

	 	The
    Executive agrees that, during his employment, he must:

 

	 	1.	use,
    communicate, copy, transfer or disclose “Confidential Information” only as necessary to fulfil his employment
    duties unless he has the Board’s prior written permission or as required by law;
	 	 	 
	 	2.	refrain
    from communicating or transferring Confidential Information through an e-mail account or system for sharing electronic records
    that is not administered by the Company; and
	 	 	 
	 	3.	take
    reasonable steps to protect Confidential Information from unauthorized use, communication, copying, transfer and disclosure
    by other employees and individuals.

 

	 	For
    purposes of this Agreement, the term Confidential Information means information in recorded or unrecorded form that is not
    generally available to the public and is generated, collected or used in the course of the Company’s current and anticipated
    business activity, including the Company’s research and development activity.
	 	 
	 	The
    Executive understands that Confidential Information does not need to be expressly marked as confidential to be protected under
    this agreement.
	 	 
	 	The
    Executive further understands that Confidential Information includes business and marketing plans, bids and proposals, lists
    of vendors, lists of suppliers, lists of consultants, plans and specifications, personal information of employees, information
    about the composition of work teams, purchasing and internal
    cost information, operating
    manuals, price and cost data, price and fee amounts, pricing and billing policies, quoting procedures, computer software and
    system information, marketing techniques and methods of obtaining business, forecasts and forecast assumptions and volumes,
    contracts, quantity and specifications of products and services purchased, leased, licensed or received by suppliers, vendors
    and consultants, confidentiality agreements, letters of intent, specifications of products and services produced, under development
    or being tested by the Company that is not public information, work product and Intellectual Property (as defined below).

 

	9.2	Confidentiality
    and Surrender of Records.

 

	 	The
    Executive agrees that, after his engagement terminates (irrespective of the circumstances under which the Executive’s
    engagement is terminated), he must immediately return all Company-owned computer equipment and all correspondence, data, records,
    memoranda, files, manuals, books, lists, operating or marketing records, magnetic tape, or electronic or other media or equipment
    of any kind which may be in the Executive’s possession or under his control or accessible to him which contain any Confidential
    Information and permanently refrain from using, communicating and disclosing Confidential Information for any reason to any
    individual or entity, unless such disclosure has been authorized in writing by the Board or is otherwise required by law.
	 	 
	 	The
    Executive acknowledges and agrees that all Confidential Information, whether in electronic or physical form, shall be the
    exclusive property of the Company or the owner thereof during the Period of Engagement and thereafter and constitutes valuable
    trade secrets of the Company or its owner, which the Company or its owner is entitled to protect.

 

    	 	 	 

    	 	-8-	 

    

 

	9.3	Covenant
    Not to Compete and Non-Solicitation.

 

	 	The
    Executive recognizes and acknowledges that, as the President and Chief Executive Officer he will have extensive
    knowledge of and contact with the Company’s suppliers, vendors, agents and employees. The Executive acknowledges that
    the Company has a material interest in preserving the relationship it has developed with its vendors, suppliers, agents and
    employees against impairment by the competitive activities of a former employee, both during the employment relationship and
    for a reasonable period of time after the cessation of employment.
	 	 
	 	The
    Executive further recognizes and acknowledges that by virtue of his position as the President and Chief Executive
    Officer of the Company he will have access to and will be entrusted with Confidential Information as defined in Section
    9.1 above relating to the Company’s operations, confidential business plans, marketing plans and other strategic confidential
    documents and information. The Executive acknowledges and agrees that he will be in
    a position to irreparably
    harm the Company should he (either during employment or following the termination of the Employee’s engagement by the
    Company) make use of the knowledge and contacts obtained during employment and for a period thereafter to the detriment of
    the Company.
	 	 
	 	The
    Executive further acknowledges and agrees that for a period of one (1) year following termination of his employment with the
    Company, he shall not, on its own behalf or on behalf of or in connection with any person, directly or indirectly, in any
    manner whatsoever including, without limitation, or as employee, principal, agent, consultant, director or shareholder attempt
    to solicit, call upon, divert or take any customers or employees away from the Company, or plan to do any of the foregoing,
    provided that the foregoing provisions shall not apply if
    the Executive is terminated
    in accordance with Section 7.1 (d) prior to the expiration of the first twelve (12) months of the Period of Engagement.

 

	9.4	Non-Disparagement:
    Litigation Assistance. The Executive and the Company agree that after the Date of Termination neither shall make,
    or cause to be made, directly or indirectly, any disparaging or derogatory statements about the other or any of their directors,
    officers, employees, shareholders or agents. The Executive also agrees that after the Date of Termination, he shall, at the
    request of the Company, render all assistance and perform all lawful acts that the Company considers necessary or advisable
    in connection with any litigation involving the Company or any director, officer, employee, shareholder, agent, representative,
    principal, customer or vendor of the Company. In the event that the Company requests the Executive’s assistance under
    this Section 9.4, the Company shall promptly pay or reimburse him for such reasonable travel expenses as he may incur in connection
    with rendering assistance thereunder.
	 	 
	9.5	Conflict
    of Interest.
	 	 
	 	It
    is a condition of the Executive’s employment that, except as provided in Section 2.3, during the period of the Executive’s
    employment with the Company, the Executive will not, without the written consent of the Company, hold an ownership position
    in any business that could be a conflict of interest to the Executive’s role and the information to which the Executive
    is privy in the exercise of the Executive’s responsibilities with the Company. Should the Executive have such an interest,
    or uncertainty regarding the appropriateness of any such interest, the Executive shall disclose this information immediately
    to the Board of the Company for consent record purposes.

 

    	 	 	 

    	 	-9-	 

    

 

	9.6	Intellectual
    Property.
	 	 
	 	“Intellectual
    Property” includes all original works of authorship, trademarks, patents, logos, designs, inventions, discoveries, developments,
    innovations, ideas, business improvements, processes, and compilations of data, whether or not subject to registration or
    capable of registration, which the Executive may solely or jointly create or conceive of during the time the Executive is
    employed by the Company, whether or not created or conceived of during normal working hours and whether or not created or
    conceived of using the Company’s resources.
	 	 
	 	The
    Executive agrees to disclose all Intellectual Property to the Company immediately after its conception or creation.
	 	 
	 	The
    Executive agrees that the Company owns the entire right, title and interest in all Intellectual Property.
	 	 
	 	The
    Executive irrevocably waives the Executive’s Moral Rights in Intellectual Property and transfers and assigns the same
    to the Company, where “Moral Rights”' means any rights to claim authorship of Intellectual Property, to
    object to any modification of Intellectual Property, and any similar right that exists under judicial or statutory law of
    any country in the world or under any treaty, regardless of whether or not such right is called or generally referred to as
    a “moral right”.
	 	 
	 	At
    the Company’s request, whether made during or after the termination of the Executive’s employment, the Executive
    agrees to execute all documents necessary for the filing of applications for a trademark, patent or any other registration,
    both Canadian and foreign, which protects the Company’s rights to Intellectual Property.
	 	 
	9.7	Definition
    of the Company. For purposes of this Section 9, the term the “Company” shall include the Company and any
    and all of its subsidiaries, ventures or affiliates.
	 	 
	9.8	Enforcement.

 

	 	(a)	The
    parties hereto agree and acknowledge that the covenants and agreements contained herein are reasonably necessary in duration
    and scope to protect the reasonable competitive business interests of the Company;
	 	 	 
	 	(b)	The
    Executive agrees that the covenants and undertakings contained in Section 9 of this Agreement relate to matters which are
    of a special, unique and extraordinary character and the Company cannot be reasonably or adequately compensated in damages
    in an action at law in the event the Executive breaches any of these covenants or undertakings. Therefore, the Executive agrees
    that the Company shall be entitled, as a matter of course, without the need to prove irreparable injury, to an injunction,
    restraining order or other equitable relief from any court of competent jurisdiction, restraining any violation or threatened
    violation of any of such terms by the Executive and such other persons as the court shall order; and

 

    	 	 	 

    	 	-10-	 

    

 

	 	(c)	Rights
    and remedies provided for in this Agreement are cumulative and shall be in addition to rights and remedies otherwise available
    to the parties under any other agreement or applicable law.

 

	10.	MISCELLANEOUS
	 	 
	10.1	Notice.
    Any notice required or permitted to be given hereunder shall be given in writing and shall be deemed sufficiently given
    if sent by recognized overnight courier services or via facsimile transmission addressed to the addressee at his or its address
    last provided to the sender in writing by the addressee for purposes of receiving notice hereunder or, unless or until such
    address shall be so furnished, to the address indicated opposite his or its signature to this Agreement.
    For purposes of this Agreement,
    notice sent in conformity with this Section 10.1 shall be deemed to have been received on the date of delivery if delivered
    by courier service or the date of transmission if
    sent by facsimile unless transmitted or delivered after business hours at the delivery location, in which case notice will
    be deemed to have been received on the next business day.
	 	 
	10.2	Modification
    and No Waiver of Breach. No waiver or modification of this Agreement shall be binding unless it is in writing signed
    by the parties hereto.
    No waiver by a party of a breach
    hereof by the other party shall be deemed to constitute
    a waiver of a future breach, whether of a similar or dissimilar nature, except to the extent specifically provided in any
    waiver under this Section 10.2.
	 	 
	10.3	Severability.
    In the event that in any legal proceedings it is determined that any section, subsection, paragraph or sub-paragraph
    of this Agreement is invalid or unenforceable, the section, subsection, paragraph or sub-paragraph will be deemed to be severed
    from the remainder of this Agreement for the purpose only of the particular proceeding. This Agreement will, in every other
    respect, continue in force and effect.
	 	 
	10.4	Governing
    Law. This Agreement shall
    be governed by and construed and interpreted in accordance with the laws of the Province of British Columbia, and all questions
    relating to the validity and performance hereof and remedies hereunder shall be determined in accordance with such law.
	 	 
	10.5	Counterparts.
    This Agreement may be executed in one or more counterparts and delivered by facsimile or other means of electronic
    transmission, each of which shall be deemed an original, but all of which taken together shall constitute one and the same
    agreement.
	 	 
	10.6	Captions.
    The captions used herein are for ease of reference only and shall not define or limit the provisions hereof.
	 	 
	10.7	Entire
    Agreement. The
    Executive acknowledges and agrees that the Company has not in any way induced the Executive to accept employment with the
    Company and that this Agreement constitutes the entire agreement between the parties hereto relating to the matters encompassed
    hereby and supersedes any prior oral or written agreements.
	 	 
	10.8	Further
    Assurances. The parties shall execute all other documents and do all farther things as may be necessary to carry out
    and give effect to the intent of this Agreement.

 

    	 	 	 

    	 	-11-	 

    

 

	10.9	Enurement.
    This Agreement shall endure to the benefit of and be binding upon the parties hereto and their respective heirs, executors,
    administrators, successors and permitted assigns.
	 	 
	10.10	Assignment.
    The rights of the Company under this Agreement may, without the consent of the Executive, be assigned by the Company
    to any person, firm, corporation, or other business entity which at any time, whether by purchase, merger, or otherwise, directly
    or indirectly, acquires all or material portions of the stock, assets or the business of the Company.
	 	 
	10.11	Non-Transferability
    of Interest. In the absence of consent by the Company, which shall not be unreasonably withheld, none of the rights
    of the Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable.
    Any attempted assignment, transfer, conveyance, or other disposition of any interest in the rights of the Executive to receive
    any form of compensation to be made by the Company pursuant to this Agreement shall be void.
	 	 
	10.12	Company
    Policies. The Executive agrees to abide by all Company policies as a term and condition of his employment and further
    acknowledges and agrees that the Company may change, alter, amend or revoke said policies from time to time.
	 	 
	10.13	Independent
    Advice. The Executive has read and understood this Agreement, has been advised by the Company to seek independent
    legal advice, and has been given the opportunity to seek and obtain such advice before signing this agreement.
	 	 
	10.14	Dispute
    Resolution.

 

	 	(a)	The
    parties agree that any dispute arising under the terms of this Agreement shall be resolved in accordance with the following
    provisions. The parties intend that the provisions of Section 10.14 of this Agreement be valid, enforceable and irrevocable.
	 	 	 
	 	(b)	The
    parties agree to utilize all reasonable efforts to resolve any dispute arising after execution of this Agreement promptly
    and in an amiable manner by negotiation between the parties. In the event that the parties are unable to resolve the dispute
    informally, either party shall provide written notice to the other asking that a meeting take place to attempt to resolve
    the dispute within fourteen (14) days of the date of the written notice. A representative of each party with authority to
    resolve the dispute shall meet.
	 	 	 
	 	(c)	If
    the dispute cannot be resolved by the meeting as described in subsection (b) 1 above, either party may refer the dispute to
    mediation. The parties will attempt to agree to a mediator with expertise in employment law matters. In the event that the
    parties are unable to agree to a mediator, either party may apply for a mediator to be appointed by the ADR Institute of Canada”)
    and the cost of the mediator shall be borne equally by the parties.

 

	10.15	Arbitration.
    Should mediation, as contemplated in subsection 10.14(c) above fail to resolve the dispute between the parties within
    fifteen (15) days after the parties have completed mediation, the dispute shall be determined by binding arbitration conducted
    in the City of Toronto, Ontario, in accordance with the applicable rules and provision of the  Arbitration Act, 1991, S.O. 1991, c. 17, that is in effect at the time that the arbitration is commenced, and a party to this Agreement seeking arbitration of a dispute shall notify the other party by notice in writing, which shall set out reasonable particulars of the dispute.

 

    	 	 	 

    	 	-12-	 

    

 

	 	(a)	The
    arbitration of the dispute shall proceed before a single arbitrator who shall be appointed by agreement of the parties provided
    that, if the parties cannot agree, the arbitrator shall be appointed by a judge of a court of competent jurisdiction located
    in the City of Toronto, Ontario.
    The arbitrator appointed
    or agreed to must be: (i) an individual admitted to practice as a lawyer in the Province of Ontario in good standing with
    the Bar Association of the Province; and (ii) a person who is independent to each of the parties to this Agreement with experience
    in arbitrating matters similar to the dispute in question.
	 	 	 
	 	(b)	The
    arbitrator shall provide a written decision that sets out in reasonable detail the basis for his decision following the conclusion
    of the arbitration without delay. A copy of the arbitrator’s decision shall be provided to each party to the arbitration.
    If a party fails to appear at any duly noticed and initiated arbitration proceeding, an award may be entered against that
    party notwithstanding such party’s failure to appear.
	 	 	 
	 	(c)	To
    the fullest extent permitted by applicable law:

 

	 	(i)	any
    controversy concerning whether a dispute is an arbitrable matter or as to the interpretation or enforceability of 10.14 of
    this Agreement shall be determined by the arbitrator; and
	 	 	 
	 	(ii)	any
    award rendered by the arbitrator shall be final, conclusive and binding (clerical errors and omissions and fraud only excepted}
    and judgment may be entered on any final and unappealable arbitration award by any provincial or federal court of competent
    jurisdiction.

 

	 	(d)	Arbitration.
All disputes, disagreements, causes of action, or claims that are in any way related to or arise out of (a) this or any other
employment agreement between Company and Executive or the validity or interpretation of this or any other such employment agreement,
(b) the rights of the parties or the performance of duties under this or any other such employment agreement, (c) the negotiations
leading up to this or any other such employment agreement or any prior or future agreements or understandings related to this
or any other such employment agreement, (d) any claimed representations or warranties that are incident to this or any other such
employment agreement or that were made or given during the course of performance of all arbitration proceedings, as well as the
fact of their occurrence, shall be kept confidential by all of the parties and may only be disclosed to their personal representatives,
their legal and other professional advisors and their services providers and others who have a legitimate “need-to-know”
or as required by law or as it necessary to confirm, correct, vacate or enforce the award. In the event of a breach of the preceding
sentence, the arbitrator is authorized to assess damages and each of the parties to this Agreement consents to the expansion of
the scope of arbitration for this purpose. The initiation of an arbitration under Section 10.14 of this Agreement shall not relieve
either party from the performance of its obligations under this Agreement and nothing in Section 10.14 of this Agreement shall
preclude a party from instituting legal action seeking relief in the nature of a restraining order, an injunction, or the like
in order to protect its rights pending the outcome of an arbitration. The arbitrator shall have authority to grant injunctive
relief, award specific performance and impose sanctions upon any party to the arbitration; provided that, no party to the arbitration
may seek, and the arbitrator shall not award, consequential, punitive or exemplary damages. All fees and costs of the arbitration
shall be allocated among the parties as determined the arbitrator, acting reasonably.

 

    	 	 	 

    	 	-13-	 

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed on this 12th day of October, 2016.

 

	BRIACELL THERAPEUTICS CORP. (THE COMPANY)	 
	 	 	 
	Per:	 	 
	 	Dr. Saeid Babaei, Chairman	 
	 	I have authority to bind the Company	 
	 	 	 
	Dr. WILLIAM V. WILLIAMS (THE EXECUTIVE)	 
	 	 	 
	Per:	 	 
	 	Dr. William V. Williams	 

 

    	 	 	 

    	 	-14-	 

    

 

SCHEDULE
“A”

 

	 	1.	Provide
    executive leadership to maximally position the Company at the forefront of the biotechnology immunotherapy industry, reporting
    directly to the Board.
	 	 	 
	 	2.	Develop
    a strategic plan to advance the Company’s mission and objectives and to advance the Company’s intellectual properties.
	 	 	 
	 	3.	Oversee
    the Company’s operations and staffing to ensure a cohesive organization.
	 	 	 
	 	4.	Liaise
    with counsel and investment bankers to oversee legal and financial operations.
	 	 	 
	 	5.	Identify,
    develop and execute financing, acquisition and merger opportunities for the Company and/or Parent Company.
	 	 	 
	 	6.	Promote
    the Company through marketing activities including representing the Company at conferences, as well as other investor relations
    activities.

 

MILESTONES
AND MILESTONE BONUSES

 

	Milestone-Based Bonuses*
	 	 	 
	 	a)	Complete
    enrollment of Patient No. 9 no later than June 30, 2017. Bonus to Executive of $7,500.
	 	 	 
	 	b)	Complete
    pre-clinical combination studies of BriaVax (or a suitable equivalent animal cell line) and a checkpoint inhibitor or any
    other agent by September 4, 2017 OR starting a second clinical study in combination with a checkpoint inhibitor or any other
    agent by September 4, 2017. Bonus to Executive of $7,500.
	 	 	 
	 	c)	Increase
    share price to no less than $0.65 per share for no less than 30 consecutive market days by the end of September 2017. Bonus
    to Executive of $15,000
	 	 	 
	 	d)	Complete
    and close a new capital raise of no less than $10,000,000 USD at not less than $0.65 per share by the end of September 2017.
    Bonus to Executive of $20,000.

 

	 	 	*	Bonuses
    will be paid within 30 days of achieving a given milestone.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]